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ABSTRACT: Severe acute respiratory coronavirus 2 (SARS-CoV-2) is a
newly identified virus that has resulted in over 2.5 million deaths globally and
over 116 million cases globally in March, 2021. Small-molecule inhibitors that
reverse disease severity have proven difficult to discover. One of the key
approaches that has been widely applied in an effort to speed up the
translation of drugs is drug repurposing. A few drugs have shown in vitro
activity against Ebola viruses and demonstrated activity against SARS-CoV-2
in vivo. Most notably, the RNA polymerase targeting remdesivir demonstrated
activity in vitro and efficacy in the early stage of the disease in humans. Testing
other small-molecule drugs that are active against Ebola viruses (EBOVs)
would appear a reasonable strategy to evaluate their potential for SARS-CoV-
2. We have previously repurposed pyronaridine, tilorone, and quinacrine
(from malaria, influenza, and antiprotozoal uses, respectively) as inhibitors of
Ebola and Marburg viruses in vitro in HeLa cells and mouse-adapted EBOV in
mice in vivo. We have now tested these three drugs in various cell lines (VeroE6, Vero76, Caco-2, Calu-3, A549-ACE2, HUH-7, and
monocytes) infected with SARS-CoV-2 as well as other viruses (including MHV and HCoV 229E). The compilation of these results
indicated considerable variability in antiviral activity observed across cell lines. We found that tilorone and pyronaridine inhibited the
virus replication in A549-ACE2 cells with IC50 values of 180 nM and IC50 198 nM, respectively. We used microscale thermophoresis
to test the binding of these molecules to the spike protein, and tilorone and pyronaridine bind to the spike receptor binding domain
protein with Kd values of 339 and 647 nM, respectively. Human Cmax for pyronaridine and quinacrine is greater than the IC50
observed in A549-ACE2 cells. We also provide novel insights into the mechanism of these compounds which is likely
lysosomotropic.
■ INTRODUCTION
As ofMarch 2021, we remain in themidst of a global health crisis
caused by a new virus that originated in Wuhan, China, in late
2019 and which has already generated unprecedented economic
and social hardship. The new coronavirus, called severe acute
respiratory coronavirus 2 (SARS-CoV-2) shares aspects of
pathology and pathogenesis with the closely related SARS-
CoV1,2 and middle east respiratory syndrome coronavirus
(MERS-CoV),3 which also belong to the same family of
Betacoronavirus. These viruses cause highly pathogenic respira-
tory infection that may lead to considerable morbidity,
mortality, and the broad range of clinical manifestations
associated with SARS-CoV-2, which has been collectively called
2019 coronavirus disease (COVID-19).4 SARS-CoV-2 infection
may result in cough, loss of smell and taste, respiratory distress,
pneumonia, and extrapulmonary events characterized by a
sepsis-like disease that require hospitalization and may lead to
death.5 Similar to SARS-CoV, SARS-CoV-2 directly interacts
with the angiotensin converting enzyme 2 (ACE2) receptor in
host cell types.6−8 Because COVID-19 is established as a new
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public health problem and vaccines are unlikely to eradicate
animal reservoirs of SARS-CoV-2, inhibition of key events
during the viral life cycle could pave the way for repurposed
drugs.
Indeed, SARS-CoV-2 spread rapidly worldwide, prompting
the World Health Organization to declare the outbreak a
pandemic, with more than 1.5 million cases confirmed in less
than 100 days. At the time of writing, there are over 116 million
confirmed cases.9 The high infection rate has caused
considerable stress on global healthcare systems, leading to
over 2.5 million deaths from COVID-19, and to date, USA has
reported the largest number of fatalities.9 Epidemic and
pandemic disease outbreaks have intensified in recent years,
and this will require various small-molecule therapeutic
interventions to be developed.
There have been many efforts globally to screen and identify
drugs for SARS-CoV-2, and there are currently clinical trials
using existing drugs that are being repurposed. One early success
was the RNA polymerase inhibitor remdesivir, which had
previously been in a clinical trial for Ebola viruses (EBOVs),10
while also demonstrating inhibition of MERS activity in rhesus
macaques11 and against many SARS-like coronaviruses,
including SARS-CoV-2 in primary human cells and in
vivo.12,13 Remdesivir demonstrated activity in Vero cells,13,14
human epithelial cells, and Calu-3 cells13 infected with SARS-
CoV-2, which justified further testing in the clinic. This drug was
then the subject of numerous clinical trials globally.15,16,49 These
included a randomized double-blind, placebo-controlled multi-
center trial that demonstrated that remdesivir reduced the days
to recovery,15 although adverse events were also higher in
treated versus placebo groups. Regardless, it quickly received an
emergency use authorization.16 A recent double-blind, random-
ized, placebo-controlled trial in adults hospitalized with
COVID-19 and who had evidence of lower respiratory tract
infection demonstrated that remdesivir was superior to placebo
in shortening the time to recovery.49 Most recently, a large
multicenter SOLIDARITY trial showed no efficacy for
hospitalized patients with COVID-19, indicating that this drug
may be more useful early in infection. This drug was also
recently approved by the Food and Drug Administration (FDA)
in October 2020.
There have also been notable failures, including hydroxy-
chloroquine, which was also initially identified as active in Vero
cells in vitro17 but repeatedly failed completely in numerous
clinical trials.18,19
Still, repurposing drugs represent possibly the fastest way to
identify a drug and bring it to the clinic with fewer potential
hurdles if it is already an approved drug or clinical candidate.20,21
There have been several large-scale high-throughput screens;
one used Huh-7 cells and tested 1425 compounds, identifying
11 with activity IC50 < 1 μM.
22 Another screen of 1528
compounds led to 19 hits in Vero cells including 4 with IC50s of
∼1 μM.23 In addition, a screen of the Prestwick library in hPSC
lung organoids identified three hits.24 A total of 12,000 clinical
stage or FDA-approved compounds in the ReFRAME library
were also screened using Vero cells, which led to 21 hits.25 To
date, we have collated well over 500 drugs that have in vitro data
from the various published in vitro studies against this
virus14,17,26,27 and used these to build a machine-learning
model that was used to select additional compounds for
repurposing and testing.28 Several of these molecules had also
previously demonstrated in vitro activity against EBOV. For
example, a machine-learning model was previously used to
identify tilorone, quinacrine, and pyronaridine tetraphosphate54
(Figure 1), all of which had inhibited EBOV and Marburg in
vitro, and they showed significant efficacy in the mouse-adapted
EBOV (ma-EBOV) model.29−32 All these molecules are also
lysosomotropic,33 which may contribute to their effect as
possible entry inhibitors.
Both chloroquine and hydroxychloroquine, its hydroxyl
derivative, are alkylated 4-aminoquinolines (4AQs).34 Quina-
crine has a side chain similar to that in chloroquine, but it is
based on an acridine nucleus, which was the first known
clinically tested antimalarial (Figure 1). This 9-aminoacridine
was discovered in 1933 following an intensive search for
synthetic quinine substitutes and was used when quinine
became practically unavailable during World War II
(WWII).35 The nucleus of the drug pyronaridine is based on
mepacrine (a 9-aminoacridine) with the addition of an
amodiaquine-like side chain35 (Figure 1). These antimalarials
have been shown to be lysosomotropic. For chloroquine and
hydroxychloroquine, this property causes 4AQs to accumulate
within lysosomes and other intracellular acidic compartments
due to protonation and sequestration of the drug.34 Uncharged
4AQs readily diffuse into the lysosome, but once protonated at
their two basic residues, they cannot diffuse back out into the
cytoplasm.34 Tilorone is an amphiphilic cationic compound and
is found to increase lysosomal pH and inhibit the ATP-
dependent acidification,36 which are characteristics of being
lysosomotropic, with an IC50 (∼4 μM), on par with the well-
known lysosomotropic compound chloroquine.32 Quinacrine
and pyronaridine have also been shown to be lysosomo-
tropic.37,38
Pyronaridine tetraphosphate is currently used as an
antimalarial in combination with artesunate (Pyramax) and
has also shown significant activity in the guinea pig-adapted
model of EBOV infection.39 Tilorone is structurally different
and is used in Eastern Europe as an antiviral for influenza.
Figure 1. Structures of tilorone, quinacrine, and tilorone.
ACS Omega http://pubs.acs.org/journal/acsodf Article
https://dx.doi.org/10.1021/acsomega.0c05996
ACS Omega 2021, 6, 7454−7468
7455
Tilorone has also demonstrated in vitro inhibition of MERS32,40
and SARS-CoV-2 with a low μM IC50 in Vero cells.
26 Most
recently, tilorone, quinacrine, and pyronaridine tetraphosphate
were demonstrated to bind to the EBOV glycoprotein. The Kd
values for pyronaridine (7.34 μM), tilorone (0.73 μM), and
quinacrine (7.55 μM) possessed higher affinity than previously
reported compounds that were found to bind to this protein.33
All three compounds have therefore made it to the clinic in
various parts of the world for other applications (e.g., malaria,
influenza, antiprotozoal, and so forth) and represent molecules
that could be viable candidates for testing in mouse-adapted
models for SARS-CoV-2. We now describe our efforts to
repurpose these molecules for SARS-CoV-2.
■ RESULTS
Cell Assays. SARS-CoV-2 susceptibility to tilorone,
quinacrine, and pyronaridine was determined in two lineages
of Vero Cells for initial screening. Unlike for Vero E6 (Figure
S1) in the Vero 76 cell line (Table 1), tilorone emerged as a
potential hit because of a 7.5-fold margin between cytotoxicity
and potency, as judged by the selectivity index (SI) (Table 1).
Moving forward to determine if these compounds were
endowed with anti-SARS-CoV-2 activity in cells more relevant
for COVID-19 pathophysiology, antiviral activity was assayed in
intestinal, respiratory, hepatic, and immune cells. Testing in a
virus yield reduction (VYR) assay on Caco-2 cells demonstrated
activity for all three molecules (Table 2) with a quinacrine EC90
of 10.54 μM (CC50 229.15 μM), a tilorone EC90 of 28.96 μM
(CC50 111.49), and a pyronaridine EC90 of 5.49 μM (CC50
51.65 μM). For comparison purposes for efficacy acrossmultiple
cell lines, these data are depicted in Figure 2.
By means of measuring the double-stranded virus RNA as a
proxy of virus replication, tilorone showed activity in Calu-3 cells
with an EC50 of 10.77 μM and selectivity index (SI) = 2 (Figure
S2). For comparison, remdesivir showed an EC50 of 0.016 μM
and an SI > 622 (Figure S2).
Tilorone was also tested in another laboratory (Dr. Thiago
Moreno, Fiocruz, Brazil) at the multiplicity of infection (MOI)
of 0.1 for 1 h at 37 °C and at different concentrations. Lysis of
the cell monolayer was performed 48 h post infection, and the
virus was titrated by plaque-forming unit (PFU) assays and
reported as % inhibition. In this assay, tilorone had an IC50 of∼9
μM and remdesivir showed almost 100% inhibition PFU/mL
even at the lowest concentration tested of 0.6 μM [Figure S3,
reported as % inhibition (A) and PFU/mL (B)].
SARS-CoV-2 can infect human hepatoma lineage (Huh-7);
however, the viral titers produced in this cell are lower than those
in Vero and Calu-3.41 While African green monkey kidney cells
(Vero E6), human hepatoma (HuH-7), and airway epithelial
cells (Calu-3)42 produced infectious SARS-CoV-2 titers and
quantifiable RNA levels, A549 pneumocytes and induced
pluripotent human neural stem cells displayed limited ability
to generate virus progeny, as measured by PFUs of the virus
below the limit of detection. In human hepatoma lineage (Huh-
7), tilorone was tested and it did not show antiviral activity up to
1 μM (Figure S4).
Tilorone was also tested for its ability to impair SARS-CoV-2
replication in human primary monocytes at 10 μM. Human
primary monocytes were infected at the indicated MOI of 0.1
and treated with 10 μM of tilorone or remdesivir for 24 h.
Remdesevir showed almost 50% inhibition of SARS-CoV-2
measured by the cell-associated viral RNA levels quantified by
real-time polymerase chain reaction (RT-PCR), when cells were
treated with 10 μM of compounds (Figure S5A). The activity of
tilorone (Figure S5A) was due to cytotoxicity (Figure S5B), and
SI = 0. Quinacrine and pyronaridine were tested on MTT
Cytotoxicity assays in human monocytes and Vero CCL81 cells
and demonstrated similar CC50 (Figure S6).
The most promising results by far were achieved in A549-
ACE2 cells which support SARS-CoV-2 growth to about 107
PFU/mL and in which quinacrine, tilorone, and pyronaridine all
showed SARS-CoV-2 inhibition demonstrating IC50 values
<200 nM (Figure 3) and good selectivity indices. This inhibition
compares well with remdesivir under the same conditions.When
cells were pretreated for 1 h with pyronaridine and tilorone prior
to the infection step, the compounds showed a higher affinity
(2−3 times) compared to incubation (when the virus was
incubated with compounds for 1 h prior to adding to the cells)
(Figure 3).
All three compounds were also tested against a group 2a
murine hepatitis virus (MHV) in DBT cells, a model of
betacoronavirus genetics and replication.43 Quinacrine showed
an IC50 of 2.3 μM, and pyronaridine showed an IC50 of 2.75 μM,
while for tilorone, the dose response curve did not reach the
plateau and the IC50 was estimated to be 20 μM (Figure 4).
These compounds were also tested in Huh-7 cells infected by
the human coronavirus 229E (HCov-229E), a group A
alphacoronavirus which infects humans and bats.44,45 It is an
enveloped, positive-sense, single-stranded RNA virus which
enters its host cell by binding to the aminopeptidase N (AP-N)
receptor.46 Quinacrine showed a decrease of 3.9 logTCID50/
mL when tested at 10 μM; pyronaridine showed a decrease of
2.83 logTCID50/mLwhen tested at 20 μM, and tilorone did not
show significant inhibition. The CC50 was >15 μM for
Table 1. EC50 and CC50 Values for Quinacrine, Pyronaridine,
and Tilorone against SARS-CoV-2 (Strain USA_WA1/2020)
in Vero 76 Cellsa





























aDrug concentration range: 0.1−100 μg/mL.
Table 2. EC90 and CC50 Values for Quinacrine and Tilorone
against SARS-CoV-2 (Strain USA_WA1/2020) in Caco-2
Cellsa
compound EC90 (μM) CC50 (μM) SI
quinacrine hydrochloride 10.54 229.15 >22
tilorone dihydrochloride 28.96 111.49 3.9
pyronaridine tetraphosphate 5.49 51.65 9.4
aDrug concentration range: 0.032−100 μg/mL. No CPE was
observed in this assay. Only VYR data were reported.
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quinacrine, and the CC50 was >20 μM for pyronaridine (Figure
S7).
Microscale Thermophoresis. Based on our previous work
showing that pyronaridine, tilorone, and quinacrine bind to
EBOV glycoprotein,33 this provided impetus to test them
against the SARS-CoV-2 spike receptor binding domain (RBD).
The Kd values for tilorone and pyronaridine were 339 and 647
nM, respectively, at pH 7.4 (Figure 5A) and 631 and 618 nM at
pH 5.2, respectively (Figure 5B). Quinacrine did not
demonstrate reproducible binding to this protein.
Vesicular Stomatitis Virus-Pseudotype SARS-CoV-2
Neutralization Assays. To directly measure the impact of
these drugs on SARS-CoV-2 S glycoprotein-mediated entry, we
employed vesicular stomatitis virus (VSV)-pseudotype SARS-
CoV-2 assays. The neutralization activity for tilorone and
pyronaridine did not achieve 50% neutralization as the dose
response curves did not reach the plateau, suggesting little if any
activity against SARS-CoV-2 spike protein-mediated docking
and entry (Figure S8 and Table S2).
■ DISCUSSION
Identifying drugs for any new virus in real time is extremely
challenging due to the pressure to identify a treatment while
large numbers of patients are suffering or dying, with only
palliative care available. The SARS-CoV-2 outbreak is only the
most recent such example. In humans, SARS-CoV-2 is currently
thought to cause a biphasic disease characterized by early high
titer virus replication in airway epithelial cells and type II
pneumocytes, followed by virus clearance and immune-
mediated pathology.47 Consequently, drug development against
Figure 2. Synopsis of the efficacy of the inhibition of SARS-CoV-2 across the multiple cell lines assessed for pyronaridine (A), tilorone (B), and
quinacrine (C). For simplicity, if no inhibition was able to be determined (i.e., IC50 > CC50), these values were arbitrarily set to 50 μM as placeholders.
Error bars (A549-ACE2 and Vero 76 only) represent the 95% CI.
Figure 3. SARS-CoV-2 inhibition in A549-ACE2 cell lines. For each compound, inhibition was assessed with either an “incubation” (the virus and
compound incubated for 1 h prior to infection) or “pretreatment” (cells incubated with the compound for 1 h prior to infection) step. Error bars for
each point as well as the calculated IC50s are shownwith their respective SEM. Each point represents aminimum of six replicates. (A) Pyronaridine, (B)
quinacrine, (C) tilorone, and (D) remdesivir.
ACS Omega http://pubs.acs.org/journal/acsodf Article
https://dx.doi.org/10.1021/acsomega.0c05996
ACS Omega 2021, 6, 7454−7468
7457
SARS-CoV-2 is complicated by the diverse disease-mediating
mechanisms associated with early direct virus cell killing and late
immune-mediated pathology.47 Studies in animals and in
humans demonstrate that early administration of direct-acting
antivirals is essential for efficacy; however, later in infection
combination therapies including direct-acting antivirals with
anti-inflammatory drugs will likely be required. Most of the
research emphasis to date has been on the development of
vaccines (with several now approved) or biologics, and only a
relatively few small molecules have made it to the clinic, such as
remdesivir.48,49 Remdesivir was originally developed for
hepatitis C viruses (HCVs) and then repurposed for EBOV;
therefore, we hypothesized that other drugs used for treating this
latter virus should also be evaluated. Our focus on repurposing
Figure 4. MHV in DBT cells, a model of SARS-Cov-2 replication. Quinacrine IC50 = 2.3 μM and pyronaridine IC50 = 2.75 μM. The tilorone dose
response curve did not reach the plateau, and the IC50 was estimated to be 20 μM.
Figure 5.MST binding analysis for the interaction between spike RBD and compounds. The concentration of labeled spike RBD is kept constant at 5
nM, while the ligand concentration varies from 250 μM and 7.629 nM. The serial titrations result in measurable changes in the fluorescence signal
within a temperature gradient that can be used to calculate the dissociation constant. The curve is shown as fraction bound [-] against compound
concentration on a log scale. The binding affinity was measured at pH 7.4 (A) and pH 5.2 (B).
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drugs for EBOV54 previously has led us to apply our approaches
to SARS-CoV-2.28 We reasoned that the three molecules
(pyronaridine, tilorone, and quinacrine) for which we already
had some antiviral knowledge of may be a useful starting point to
explore for repurposing for SARS-CoV-2 and, based on our
results, further suggest that these compounds should be
evaluated in SARS-CoV-2 mouse models.
Several groups have now published on these three drugs;49,50
pyronaridine51 and tilorone26,52 are in clinical trials in different
countries for SARS-CoV-2. Tilorone was previously identified in
vitro in Vero cells as a hit against SARS-CoV-2 (IC50 4 μM)
26
and has also been shown to have similar activity against MERS41
and Ebola53 (as has remdesivir11). Tilorone was recently found
to block the endocytosis of preformed α-Syn fibrils and was an
inhibitor of heparan sulfate proteoglycan (HSPG)-dependent
endocytosis.54 Combined with our earlier findings of tilorone
binding to the EBOV glycoprotein,33 this would suggest that at
minimum a partial direct antiviral effect rather than an effect on
the innate immune system (as long assumed since the 1970s)32
is responsible for the efficacy observed in this case. In our hands,
tilorone has also shown antiviral activity against SARS-CoV-2 in
A549-ACE2 (IC50 180 nM), in Vero 76 cell lines (IC50 of 6.62
μM) but not Vero E6, and to a lesser extent in Caco-2 and Calu-
3.
Pyronaridine is used in combination with artesunate to treat
malaria.55 We have previously demonstrated that both
molecules show additivity against EBOV.56 Pyronaridine was
therefore of interest to us as a potential antiviral against SARS-
CoV-2. More recently, pyronaridine was tested again in Vero
cells by others (IC50 1.08 μM, CC50 37.09 μM) at 24 hpi and in
Calu-3 cells (IC50 6.4 μM, CC50 43.08 μM) at 24 hpi.
50 Our
results do not match any of these earlier data as we showed no
activity in Vero 76, Vero E6 cells, and Calu-3 cells, while we did
see activity in Caco-2 (EC90 5.49 μM), A549-ACE2 cells (IC50 =
198 nM), and MHV (IC50 2.75 μM).
A recent screen of the Prestwick library in hPSC lung
organoids identified the antiprotozoal quinacrine (EC50 2.83
μM)57 which was followed up in mice infected with the SARS-
CoV-2 pseudovirus and showed a significant decrease in infected
cells.57 Others have not observed significant in vitro SARS-CoV-
2 activity for quinacrine in Vero cells,26 while it has previously
been demonstrated to possess activity against Ebola-infected
HeLa cells53 but not Vero cells.29 In this study, we confirm no in
vitro activity in Vero E6, Vero76, and Calu-3 but demonstrate
activity in Caco-2 (EC90 10.54 μM), A549-ACE2 (IC50 122
nM), and MHV (IC50 2.3 μM) for quinacrine.
These three drugs have therefore shown considerable
variability in testing in different cell types infected with SARS-
CoV-2 (Table S1) as compared to the recent literature. The
differences between these and previous data published in Vero
cells could be due to a number of factors including differences in
assays,MOI, time of addition of the drug and expression levels of
ACE2. It should also be clear that we see differences in the data
reported for these compounds as well. These three drugs have all
demonstrated low μM activity against SARS-CoV-2 in the best
cases, and while A549-ACE2 appears especially sensitive to
these drugs, the effectiveness of the remdesivir control is in line
with published data from different cell lines.13 Our observations
of no inhibition in Vero E6 cells for tilorone, quinacrine, and
pyronaridine are exactly as we had observed previously for
EBOV.58 The gold standard currently is primary human airway
epithelial cells or a primary type II ATII cell as are targeted by
the virus in vivo.
We characterized binding of pyronaridine and tilorone to the
spike RBD using microscale thermophoresis (MST), with Kd
values for tilorone and pyronaridine of 339 and 647 nM,
respectively (Figure 5). Pyronaridine and tilorone bind to the
spike RBD with 20−40 times weaker affinity when compared to
ACE2, which has been reported to be ∼15 nM by different
techniques.59,60 In the VSV-pseudotype SARS-CoV-2 neutral-
ization assay, we saw no measurable activity for tilorone and
pyronaridine (Figure S6 and Table S2), suggesting that it may be
necessary to modify these compounds to increase affinity for the
spike protein to enhance activity. The binding affinity
experiments using MST were performed with the RBD, which
is the RBD that binds to ACE2. Despite these compounds
binding to the spike RBD, their affinity is clearly not high enough
to compete with binding to ACE2 in the pseudovirus assay and
the compounds may bind to the RBD in a location that does not
affect binding to the ACE2 receptor. We have previously
characterized that these compounds are lysosomotropic,56 so
this may also be their mechanism of action against SARS-CoV-2,
but this will require a significant amount of work outside the
scope of this paper to confirm.
The effect of lysosomotropic compounds on cells is
multifaceted as evidenced by the prototypical lysosomotropic
compound chloroquine. A well-known antiviral effect of
chloroquine is against EBOV and has been associated with the
pH increase within lysosomes, which reduces the efficiency of
acid hydrolases (cathepsins) required for viral glycoprotein
priming.61 As there is some evidence that cathepsin is also
involved in one entry mechanism of SARS-CoV-2, this function
may also be involved in the partial inhibition of SARS-CoV-2 by
compounds of this class, although it is unlikely the only
mechanism of inhibition by lysosomotropic compounds.
Interestingly, SARS-CoV-2 has recently been shown to also
increase the pH of lysosomes, possibly through the open reading
frame protein 3A (ORF3a).62 As the sarbecovirus E protein also
functions as a viroporin, these overlapping activities are likely
requisites for efficient SARS-CoV-2 infection.63−66 ORF3a has
been shown to traffic to lysosomes and disrupt their acidification
and ultimately viral egress.62 ORF3a is also a viroporin, which
modifies several cellular functions, including membrane
permeability, membrane remodeling, and glycoprotein traffick-
ing.67 While lysosomotropic compounds have been shown to
increase lysosomal pH, this effect has been demonstrated to be
transient with multiple lysosomotropic compounds including
chloroquine, fluoxetine, tamoxifen, and chlorpromazine. This
was illustrated by multiple types of measurements, including a
lack of a decrease in cathepsin activity over time.68 It is possible
that since cells are able to counter the pH change caused by the
lysosomotropic compounds, this may translate into this same
phenomenon with SARS-CoV-2-infected cells. If an increased
pH of the lysosome is indeed required for the efficient egress of
the virus, compounds that counteract this would potentially act
as an antiviral. The “redundant” viroporin activities of E protein
and ORF3a may also complicate the specificity and potency of
lysosomotropic compounds if they target one but not both
proteins. This is consistent with the ability to delete either one
separately and still have a viable virus, yet if both are deleted,
then the virus is inhibited. Consequently, lysosomotropic
inhibitors must target both activities.
While a pH change in acidic organelles is themost well-known
effect of lysosomotropic compounds, they are also known to
elicit other cellular effects such as inducing vacuole for-
mation69,70 by the fusion of lysosomes and late endosomes.71
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This is an important distinction because a precursor to this is a
general disorganization of the Golgi complexes with an
increased number of vesicles found proximal to the Golgi.70
Therefore, lysosomotropic compounds not only create vacuoles
but also cause the disruption of vesicle translation from theGolgi
to distal subcellular locations.72−74 Many lysosomotropic
compounds have shown a similar disruption in vesicle
trafficking, including transport to the apical plasma mem-
brane.75,76 Disruption of this translocation of vesicles from the
trans golgi network (TGN) would likely inhibit the common
biosynthetic secretory pathway used for egress of multiple
viruses such as HCVs, dengue viruses, and West Nile
viruses.77,78 Additionally, many drugs that are known to be
lysosomotropic also induce phospholipidosis in cells,79 which is
the reduced degradation of phospholipids, causing an excess
accumulation in cells. The mechanism of drug-induced
phospholipidosis is unclear but could be due to the cationic
drug binding to bis(monoacylglycero)phosphate (BMP) in the
phospholipid bilayer, which is heavily enriched within the
lysosome membrane.80 This affects the efficiency of acid
hydrolases as well as disrupts interactions between membrane-
bound proteins and molecules within the lysosomal lumen.
Drug-induced phospholipidosis is also suggested to alter the
lysosomal membrane curvature81 similar to pH.82 A change in
membrane curvature is a phenomenon suggested to be
important for the membrane fusion of other viruses,83 which
points to a similar effect on the membrane fusion of SARS-CoV-
2. Multiple cellular alterations by lysosomotropic compounds
may be involved in the inhibition of SARS-CoV-2 egress.
Despite the compounds binding to the RBD, the affinity is
20−40 times lower as compared to binding to ACE2. Figure 3
shows that when cells were pretreated for 1 h with pyronaridine
and tilorone prior to the infection step, the compounds showed a
higher affinity (2−3 times) compared to incubation (when the
virus was incubated with compounds for 1 h prior to adding to
the cells). This supports the hypothesis that the mechanism
relies more on a host effect than on an effect on the virus, which
further supports one of the mechanisms we proposed,
specifically the lysosomotropic aspect of the compounds. It
has also been demonstrated that the uptake of weak bases into
lysosomes is a progressive process, which may take 20−60 min
or longer to go to completion,1 so a longer pretreatment time
may show various effects. The difference in inhibition between
incubation and pretreatment is statistically significant for both
tilorone and pyronaridine. Pyronaridine and tilorone are
stronger lysosomotropic compounds than quinacrine, which is
based on their ability to inhibit lysotracker red.56 This could be
one explanation why pretreatment with tilorone and pyronar-
idine has lower IC50s than those with incubation (virus +
compound) and why this does not occur with quinacrine.
The relevance of pyronaridine, tilorone, and quinacrine as
antivirals can be further assessed using their concentrations
attained in vivo. The Cmax data in our previous mouse
pharmacokinetics studies (intraperitoneal dosing) suggests
that the concentration is above the average IC50 observed for
EBOV inhibition in vitro (∼1 μM) (Table S2). For quinacrine
and pyronaridine, we have also identified published human
pharmacokinetics data, and these suggest that IC50 values up to 1
μM would be below the Cmax achieved for quinacrine and
pyronaridine (Table S3). Therefore, as we have demonstrated
IC50 values in some cell lines infected with SARS-CoV-2 around
or below 1 μM this may enable them to achieve efficacious
concentrations. While we could not find human pharmacoki-
netics data for quinacrine, it can still be considered as it was
safely used during WWII in millions of soldiers as an
antimalarial.29 These three molecules generally have excellent
in vitro ADME properties, and there is a considerable body of
data that we have built up on them (Table S4) including the
maximum tolerated dose in mice. This would certainly be useful
for designing efficacy assessment studies in SARS-CoV-2-
infected mouse models in future.
It is important to study virus infection in different cell lines
and understand the subtle differences among them when treated
with drugs. SARS-CoV-2 infection experiments using primary
human airway epithelial cells have been found to have CPEs 96 h
after the infection.84 However, primary human airway epithelial
cells are expensive and do not proliferate indefinitely.85 Several
infinitely proliferating cell lines, such as Caco-2,86 Calu-3,87
HEK293T,88 and Huh7,87 have been utilized in SARS- CoV-2
infection experiments. These cell lines do not accurately mimic
human physiological conditions and generate low titers of
infectious SARS-CoV-2.86−88 Despite this limitation, valuable
information about the virus infection and replication can be
learned from studies using these cell lines. A previous study89
assessed 25 cell lines derived from different tissues or organs and
host species and reported that CPEs were only seen in VeroE6
and FRhK4 cells after SARS-CoV-2 inoculation for up to 120
hpi. These findings are important for optimization of antiviral
assays based on cell protection assessment because cell lines
without obvious CPEs might lead to overestimation of cell
viability and drug efficacy.89 For efficient SARS-CoV-2 research,
a cell line, such as Vero cells, that can easily replicate and isolate
the virus is essential, but they have been shown not to produce
interferons (IFNs) when infected with Newcastle disease
viruses, rubella viruses, and other viruses.90 Under previously
described experimental conditions, productive SARS-CoV-2
replication in A549 cells was erratic,41 which can be overcome by
preparing A549 cells overexpressing ACE2 (as used in the
current study).
The differences in responses in different cell lines could be
accounted for by the basic biochemistry, for example, hepatic
cells, like Huh-7, are equipped with enzymes to synthesize
nucleotides, carbohydrates, and lipids.91 Hence, it is not
surprising that the highest potency of remdesivir against
SARS-CoV-2 is found in Huh-7 cells, followed by Calu-3 and
Vero, implying that Huh-7 and subsequently Calu-3 are active to
convert it to its triphosphate.41,92
SARS-CoVs that enter the host via the respiratory tract,
airway and alveolar epithelial cells, vascular endothelial cells, and
alveolar macrophages are among their first targets of viral
entry.93 Viral entry may depend as well on the expression of
TMPRSS2 because nearly undetectable amounts of ACE2 still
support SARS-CoV entry as long as TMPRSS2 is present.94 The
SARS-CoV-2 spike contains a furin cleavage site, thus reducing
the dependence of SARS-CoV-2 on target cell proteases
(TMPRSS2/cathepsin L) for entry,95,102 and furin is abundantly
expressed in human bronchial epithelial cells, thus potentially
extending its cellular tropism.96
While the nasal airway epithelium replicates the virus best
early,97 Type II pneumocytes are the most affected cells in the
lung of patients that died from COVID-19.98 Both A549 and
Calu-3 cells are lung epithelial cells (based on ATCC
information). Under continuous submersible culture, A549
cells decrease the expression of the type C surfactant and
enhances the expression of aquaporin V, a phenotype of type I
pneumocytes.99 Calu-3 is an airway epithelial cell that can be
ACS Omega http://pubs.acs.org/journal/acsodf Article
https://dx.doi.org/10.1021/acsomega.0c05996
ACS Omega 2021, 6, 7454−7468
7460
induced to differentiate into a ciliated airway epithelial cell.42
For entry inhibitors, Calu-3 is a better model than Vero and
A549 cells because Calu-3 expresses TMPRSS2. The lack of
antiviral activity of chloroquine in Calu-3 cells would likely have
anticipated its failure in clinical trials.100 Under regular cell
culture, Calu-3 and Caco-2 better support virus entry than
A549;89,101 however, the latter are much easier to grow,
reinforcing the interest in generating A549-ACE2 cells which
replicate SARS-CoV-2 to titers of ∼107 PFU/mL.
■ CONCLUSIONS
In conclusion, this study shows the importance of an exhaustive
comparison of different cell lines when testing small molecules
as inhibitors of SARS-CoV-2 and clearly indicates how subtle
differences in experimental approaches with the same cell lines
can have dramatic effects on whether a drug is identified as an
inhibitor or not.We illustrate this now for Vero cells which when
infected with Ebola or SARS-CoV-2 are insensitive to
quinacrine, tilorone, and pyronaridine.58 This may be related
to the mechanism of entry in these cells, the lack of IFNs in Vero
cells, or other factors that limit activity for these lysosomotropic
compounds.56 While they are not as potent inhibitors against
SARS-CoV-2 as remdesivir in most cell types, they are
comparable in the A549-ACE2 cell line. Future work will
focus on testing the efficacy of these drugs against SARS-CoV-2
in animal models and further interrogation of the mechanism.
■ METHODS
Chemicals and Reagents. Pyronaridine tetraphosphate [4-
[(7-chloro-2-methoxybenzo[b][1,5]naphthyridin-10-yl)-
amino]-2,6-bis(1-pyrrolidinylmethyl)phenol phosphate
(1:4)]54 was purchased from BOC Sciences (Shirley NY).
Tilorone and quinacrine were purchased from Cayman
Chemicals (Ann Arbor, Michigan). The purity of these
compounds is greater than 95%.
Cell Assays. Vero E6 Cells. All drugs were tested with Vero
E6 cells as described recently.102 Cells were plated in opaque 96-
well plates 1 day prior to infection. Drug stocks were made in
dimethyl sulfoxide (DMSO), water, or methanol. Drugs were
diluted from the stock to 50 μM and an eight-point 1:2 dilution
series made. Cells were pretreated with the drug for 2 h at 37 °C
and 5% CO2 prior to infection at an MOI of 0.01 or 0.004.
Vehicle controls were used on every plate, and all treatments
were performed in triplicate for each screen. In addition to plates
that were infected, parallel plates were left uninfected to monitor
cytotoxicity of the drug alone. Three independent screens with
this setup were performed. Cells were incubated at 37 °C and 5%
CO2 for 3 days before CellTiter-Glo assays were performed as
per the manufacturer’s instructions (Promega). Luminescence
was read using a Molecular Devices SpectraMax L plate reader.
Vero 76 Cell Reduction of the Virus-Induced Cytopathic
Effect (Primary CPE Assay). Confluent or near-confluent cell
culture monolayers of Vero 76 cells are prepared in 96-well
disposable microplates the day before testing. Cells are
maintained in the minimum essential medium (MEM)
supplemented with 5% fetal bovine serum (FBS). For antiviral
assays, the same medium is used but with FBS reduced to 2%
and supplemented with 50 μg/mL gentamicin. Compounds are
dissolved in DMSO, saline, or the diluent requested by the
submitter. Less soluble compounds are vortexed, heated, and
sonicated, and if they still do not go into the solution, they are
tested as colloidal suspensions. The test compound is prepared
at four serial log10 concentrations, usually 0.1, 1.0, 10, and 100
μg/mL or μM (as per the sponsor’s preference). Lower
concentrations are used when an insufficient compound is
supplied. Five microwells are used per dilution: three for
infected cultures and two for uninfected toxicity cultures.
Controls for the experiment consist of six microwells that are
infected and not treated (virus controls) and six that are
untreated and uninfected (cell controls) on every plate. A known
active drug is tested in parallel as a positive control drug using
the same method as is applied for test compounds. The positive
control is tested with every test run.
Growth media are removed from the cells, and the test
compound is applied in a 0.1 mL volume to wells at a 2×
concentration. The virus, normally at an ∼60 CCID50 (50% cell
culture infectious dose) in a 0.1 mL volume is added to the wells
designated for virus infection. The medium devoid of the virus is
placed in toxicity control wells and cell control wells. Plates are
incubated at 37 °C with 5% CO2 until marked CPE (>80% CPE
for most virus strains) is observed in virus control wells. The
plates are then stained with 0.011% neutral red for
approximately 2 h at 37 °C in a 5% CO2 incubator. The neutral
red medium is removed by complete aspiration, and the cells
may be rinsed 1× with phosphate-buffered solution (PBS) to
remove the residual dye. PBS is completely removed, and the
incorporated neutral red is eluted with 50% Sorensen’s citrate
buffer/50% ethanol for at least 30 min. The neutral red dye
penetrates living cells; thus, the more intense the red color, the
larger the number of viable cells present in the wells. The dye
content in each well is quantified using a spectrophotometer at a
540 nm wavelength. The dye content in each set of wells is
converted to a percentage of the dye present in untreated control
wells using a Microsoft Excel computer-based spreadsheet and
normalized based on the virus control. The 50% effective (EC50,
virus-inhibitory) concentrations and 50% cytotoxic (CC50, cell-
inhibitory) concentrations are then calculated by regression
analysis. The quotient of CC50 divided by EC50 gives the SI
value. Compounds showing SI values≥ 10 are considered active.
Vero 76 Cell Reduction of Virus Yield (Secondary VYR
Assay). Active compounds are further tested in a confirmatory
assay. This assay is set up like the methodology described above,
and only eight half-log10 concentrations of the inhibitor are
tested for antiviral activity and cytotoxicity. After sufficient virus
replication occurs (3 days for SARS-CoV-2), a sample of the
supernatant is taken from each infected well (three replicate
wells are pooled) and tested immediately or held frozen at −80
°C for later virus titer determination. After maximum CPE is
observed, the viable plates are stained with the neutral red dye.
The incorporated dye content is quantified as described above to
generate the EC50 and CC50 values. The VYR test is a direct
determination of how much the test compound inhibits virus
replication. The virus yielded in the presence of the test
compound is titrated and compared to virus titers from the
untreated virus controls. Samples were collected 3 days after
infection. Titration of the viral samples (collected as described in
the paragraph above) is performed by endpoint dilution.103
Serial 1/10 dilutions of the virus are made and plated into four
replicate wells containing fresh cell monolayers of Vero 76 cells.
Plates are then incubated, and cells are scored for the presence or
absence of the virus after distinct CPE is observed (3 days after
infection); the CCID50 is calculated using the Reed−Muench
method.103 The 90% (one log10) effective concentration (EC90)
is calculated by regression analysis by plotting the log10 of the
inhibitor concentration versus log10 of the virus produced at
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each concentration. Dividing EC90 by the CC50 gives the SI value
for this test.
Yield-Reduction Assays in Monocytes, Calu-3, and
Huh-7. Human hepatoma lineage (Huh-7), the lung epithelial
cell line (Calu-3), or human primary monocytes from healthy
donors (5 × 10 × 105 cell/well in 24-multiwell plates) were
infected at an MOI of 0.1 for 1 h at 37 °C and treated with
different concentrations of the compounds. Lysis of the cell
monolayer was performed 24 h (for monocytes) or 48 h (for
Huh-7 and Calu-3 cells) post infection, and the culture
supernatant was harvested 48 h post infection; the virus was
titrated by PFU assays in Vero E6 cells. Alternatively, cell-
associated viral genomic (ORF1b) and subgenomic (ORFE)
RNAwas quantified by RT-PCR.104 The standard curve method
was employed for virus quantification. For reference to the cell
amounts used, the housekeeping gene RNAse P was amplified.41
Calu-3 Cells. Calu-3 (ATCC, HTB-55) cells were pretreated
with test compounds for 2 h prior to continuous infection with
SARS-CoV-2 (isolate USA WA1/2020) at an MOI of 0.5. 48 h
post infection, cells were fixed, immunostained, and imaged by
automated microscopy for infection (dsRNA + cells/total cell
number) and cell number. Sample well data were normalized to
aggregated DMSO control wells and plotted versus drug
concentration to determine the IC50 (infection: blue) and
CC50 (toxicity: green).
Caco-2 Cell Virus Yield Reduction. For the Caco-2 VYR
assay, the methodology is identical to the Vero 76 cell assay
other than the insufficient CPE observed on Caco-2 cells to
allow EC50 calculations. The supernatant from the Caco-2 cells
is collected on day 3 post infection and titrated on Vero 76 cells
for virus titer as before.
A549-ACE2 Cells. A549-ACE2 cells were plated in Corning
black-walled clear bottom 96-well plates 24 h before infection
for confluency. Drug stocks were diluted in DMSO for a 200×
concentration in an eight-point 1:4 dilution series. Prepared
200× dilutions were then diluted to a 2× concentration in
infection media [Gibco Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 5% HyClone FetalCloneII, 1%
Gibco NEAA, 1% Gibco Pen-Strep]. Growth media were
removed, and cells were pretreated with a 2× drug for 1 h prior
to infection at 37 °C and 5% CO2. Cells were either infected at
an MOI of 0.02 with the infectious clone SARS-CoV-2-nLuc97
or mock-infected with infection media to evaluate toxicity.
Effects of compounds to the virus were also evaluated by
incubating the virus at anMOI of 0.02 with compounds 1 h prior
to the infection step. In this step, cell media were removed and
1× of the virus at an MOI of 0.02 was added to the cells. 48 h
post infection, wells were treated with Nano-Glo luciferase assay
activity to measure viral growth or the CytoTox-Glo
Cytotoxicity assay to evaluate toxicity of drug treatments,
performed as per the manufacturer’s instructions (Promega).
Nano-Glo assays were read using a Molecular Devices
SpectraMax plate reader, and CytoTox-Glo assays were read
using a Promega GloMax plate reader. Vehicle-treated wells on
each plate were used to normalize replication and toxicity. Drug
treatment was performed in technical duplicate and biological
triplicate.
VSV-Pseudotype SARS-CoV-2 Neutralization Assays.
Tilorone dihydrochloride, quinacrine hydrochloride, and
pyronaridine tetraphosphate were tested for neutralization
activity against the SARS-CoV-2 spike protein using a VSV-
pseudotyped (rVSV-SARS-CoV-2 S) neutralization assay in
Vero ATCC CCL-81 [IBT Bioscience (Rockville, MD)]. The
luciferase-based microneutralization assay was conducted in
Vero cells seeded in black 96-well plates on day 1 at 6.00 × 104
cells per well. Eight serial dilutions were prepared in triplicate
and incubated for 1 h with approximately 10,000 RLU of rVSV-
SARS-CoV-2; the virus only and cells only were added for
controls and calculations. The TA/virus mixture was then added
to the Vero cells, and the plates were incubated for 24 h at 37 °C.
Firefly luciferase activity was detected using the Bright-Glo
Assay System kit (Promega). The 50% inhibition concentration
(IC50) was calculated using the XLfit dose response model.
Murine Hepatitis Virus. Each compound was tested for
antiviral activity against MHV, a group 2a betacoronavirus, in
DBT cells. Each compound was tested against MHV using an
eight-point dose response curve consisting of serial 4-fold
dilutions, starting at 10 μM. Cytotoxicity of these compounds
was not performed in this cell line, and there was no discernible
cytotoxic effect of the compounds at the dosages tested.
HCoV 229E Antiviral Assay. HCoV 229E (a gift from
Ralph Baric, UNC, Chapel Hill) was propagated on Huh-7 cells,
and titers were determined by the TCID50 assay on Huh-7 cells.
Huh-7 cells were plated at a density of 25,000 cells per well in 96-
well plates and incubated for 24 h at 37 °C and 5% CO2. Cells
were infected with HCoV 229E at an MOI of 0.1 in a volume of
50 μL ofMEM 1 + 1 + 1 [modified Eagle’s medium, 1% FBS, 1%
antibiotics, 1% N-(2-hydroxyethyl)piperazine-N′-ethanesul-
fonic acid (HEPES) buffer] for 1 h. The virus was removed,
cells were rinsed once with PBS, and compounds were added at
the indicated concentrations in a volume of 100 μL. Super-
natants were harvested after 24 h, which were serially 10-fold
diluted, and virus titer was determined by the TCID50 assay on
Huh-7 cells. CPE was monitored by visual inspection at 96 h
post infection. TCID50 titers were calculated using the
Spearmann-Karber method.105,106
Cytotoxicity. Cytotoxicity of compounds was assessed by
the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) assay for quantification of cellular mitochondrial
activity as an indirect measurement of cell viability. Briefly,
freshly collected peripheral bloodmononuclear cells were plated
in a 96-well plate at a concentration of 105 cells/well in the
RPMI medium for 2 h to allow adhesion of monocytes. The
RPMI medium was then changed for a complete medium
supplemented with proper drug concentrations and controls for
24 h at 5% CO2 and 37 °C. Vero CCL81 cells were cultivated at
5% CO2 and 37 °C using DMEM supplemented with 10% heat-
inactivated FBS. For this experiment, Vero cells were seeded at a
density of 104 cells/well in a 96-well plate prior to incubation
with a serial dilution of compounds of interest and controls for
72 h. After drug treatment, cells were next incubated with MTT
(Sigma-Aldrich M5655) for 4 h, followed by formazan crystal
solubilization with isopropanol and absorbance readings at
OD570.
107 Cellular viability was expressed as a percentage
relative to the vehicle-treated control. The CC50 was defined as
the concentration that reduced the absorbance of treated cells to
50% when compared to non-treated controls. For Huh-7 cells,
the cytotoxicity of extracts and pure compounds was determined
according to the manufacturer’s instructions using the CytoScan
LDH cytotoxicity assay (G-Biosciences, St. Louis, MO). Briefly,
25,000 Huh-7 cells per well were added to 96-well plates and
incubated for 24 h at 37 °C and 5% CO2. Compounds were
added with fresh media at the indicated concentrations to
triplicate wells for 24 h. Following the incubation, the plates
were centrifuged at 250g for 5 min and 50 μL of the supernatant
from each well was transferred to a new plate. An equal volume
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of the substrate mix was added to each well and the plates
incubated at room temperature for 30m. Then, the stop solution
was added, and the absorbance was measured at 490 nm using a
plate reader (Synergy HT, BioTek, Winooski, VT). The percent
cytotoxicity was determined using the following formula:
(experimental-spontaneous absorbance/maximum-spontane-
ous absorbance) × 100.
Expression and Purification of the Spike RBD of SARS-
CoV-2. A codon-optimized gene encoding for SARS-CoV-2
(331−528 amino acids, QIS60558.1) was expressed in Expi293
cells (Thermo Fisher Scientific) with human serum albumin
secretion signal sequence and fusion tags (6× Histidine tag,
Halo tag, and TwinStrep tag) as described before.108 The S1
RBD was purified from the culture supernatant by nickel−
nitrilotriacetic acid agarose (Qiagen), and the purity was
confirmed to be >95% as judged by coomassie-stained sodium
dodecyl sulfate-polyacrylamide gel electrophoresis. The purified
RBD protein was buffer-exchanged to 1× PBS prior to analysis
by MST.
Microscale Thermophoresis. Experiments were per-
formed using a Monolith Pico (NanoTemper). Briefly, 10 μM
protein was labeled using aMonolith Protein Labeling Kit RED-
NHS 2nd Generation (Amine Reactive), with threefold excess
NHS dye in PBS (pH 7.4). The free dye was removed according
to the manufacturer’s instruction, and the protein was eluted in
the MST buffer [N-(2-hydroxyethyl)piperazine-N′-ethanesul-
fonic acid (HEPES) 10 mM pH 7.4, NaCl 150 mM] and
centrifuged at 15 k rcf for 10 min. Binding affinity measurements
were performed using 5 nM protein a serial dilution of
compounds, starting at 250 μM. For each experimental
compound, 16 independent stocks were made in DMSO using
a 2-fold serial dilution (10 mM initial concentration). 19.5 μL of
the spike RBD (5 nM) of the labeled protein in the MST buffer
containing 0.1% Triton X-100 and 1 mM β-mercaptoethanol
(BME) was combined with 0.5 μL of the compound stock and
then mixed thoroughly. This resulted in 2-fold serial dilution
testing series with the highest and lowest concentrations of 250
μM and 7.629 nM, respectively, with a consistent final DMSO
concentration of 2.5%. The protein was incubated on ice in the
presence of compounds for 1 h prior to transferring to standard
Monolith NT.115 capillaries. Experiments were run at 20%
excitation and a high MST power at 23.0 °C on a Monolith
NT.115Pico (NanoTemper). Each experimental compoundwas
run in triplicate.
The data were obtained with MO.Control 1.6.1 (Nano-
Temper Technologies). Recorded data were analyzed with
MO.Affinity Analysis 2.3 (NanoTemper Technologies). The
dissociation constant Kd quantifies the equilibrium of the
reaction of the labeled molecule A (concentration cA) with its
target T (concentration cT) to form the complex AT
(concentration cAT) and is defined by the law of mass action
as Kd = cAxcT/cAT, where all concentrations are “free”
concentrations. During the titration experiments, the concen-
tration of the labeled molecule A is kept constant and the
concentration of added target T is increased. These concen-
trations are known and can be used to calculate the dissociation
constant. The free concentration of the labeled molecule A is the
added concentration minus the concentration of the formed
complex AT. The Kd is calculated as =









The fraction of bound molecules x can be derived from Fnorm,
where Fnorm(A) is the normalized fluorescence of only unbound
labeled molecules A and Fnorm(AT) is the normalized
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Herrler, T.; Erichsen, S.; Schiergens, T. S.; Herrler, G.; Wu, N.-H.;
Nitsche, A.;Müller, M. A.; Drosten, C.; Pöhlmann, S. SARS-CoV-2 Cell
Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically
Proven Protease Inhibitor. Cell 2020, 181, 271−280.
(102)Weston, S.; Coleman, C.M.; Haupt, R.; Logue, J.; Matthews, K.;
Li, Y.; Reyes, H. M.; Weiss, S. R.; Frieman, M. B. Broad Anti-
coronavirus Activity of Food and Drug Administration-Approved
Drugs against SARS-CoV-2 In Vitro and SARS-CoV In Vivo. J. Virol.
2020, 94, e01218−20.
(103) Reed, L. J.; Muench, H. A Simple Method of Estimating Fifty
per Cent Endpoints12. Am. J. Hyg. 1938, 27, 493−497.
(104) Wölfel, R.; Corman, V. M.; Guggemos, W.; Seilmaier, M.;
Zange, S.; Müller, M. A.; Niemeyer, D.; Jones, T. C.; Vollmar, P.; Rothe,
C.; Hoelscher, M.; Bleicker, T.; Brünink, S.; Schneider, J.; Ehmann, R.;
Zwirglmaier, K.; Drosten, C.; Wendtner, C. Virological assessment of
hospitalized patients with COVID-2019. Nature 2020, 581, 465−469.
(105) Spearman, C. The method of ‘right and wrong cases’ (‘constant
stimuli’) without Gauss’s formulae. Br. J. Psychol 1908, 2, 227−242.
(106) Kärber, G. Beitrag zur kollektiven behandlung pharmakolo-
gischer reihenversuche. Naunyn-Schmiedebergs Arch. Exp. Pathol.
Pharmakol. 1931, 162, 480−483.
(107) Kumar, P.; Nagarajan, A.; Uchil, P. D. Analysis of Cell Viability
by the MTT Assay. Cold Spring Harb. Protoc. 2018, 2018,
pdb.prot095505.
(108) Premkumar, L.; Segovia-Chumbez, B.; Jadi, R.; Martinez, D. R.;
Raut, R.; Markmann, A.; Cornaby, C.; Bartelt, L.; Weiss, S.; Park, Y.;
Edwards, C. E.; Weimer, E.; Scherer, E. M.; Rouphael, N.; Edupuganti,
S.; Weiskopf, D.; Tse, L. V.; Hou, Y. J.; Margolis, D.; Sette, A.; Collins,
M. H.; Schmitz, J.; Baric, R. S.; de Silva, A. M. The receptor binding
domain of the viral spike protein is an immunodominant and highly
specific target of antibodies in SARS-CoV-2 patients. Sci. Immunol.
2020, 5, No. eabc8413.
ACS Omega http://pubs.acs.org/journal/acsodf Article
https://dx.doi.org/10.1021/acsomega.0c05996
ACS Omega 2021, 6, 7454−7468
7468
